NXB 5886

Drug Profile

NXB 5886

Alternative Names: NXB-5886

Latest Information Update: 18 Apr 2011

Price : $50

At a glance

  • Originator Nymox Pharmaceutical Corporation
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Streptococcal infections

Most Recent Events

  • 08 Aug 2005 This compound is still in active development
  • 14 Apr 2003 This compound is still in active development
  • 03 Oct 2001 Preclinical development for Streptococcal infections in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top